Abrysvo or Arexvy Market 2026 evolving with RSV vaccine demand

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Abrysvo Or Arexvy Market Expected To Change Between 2026 And 2030?

Several factors underpinned the historical growth, including the unmet need for RSV vaccines, an expanding aging population, the significant burden posed by respiratory infections, successful regulatory approvals, and a rise in public health awareness.

Growth during the forecast period is expected due to an expanding elderly demographic, increasing rsv hospitalization rates, broader recommendations for vaccination, improved access through healthcare providers, and a stronger focus on preventive healthcare.

Key trends anticipated in the forecast period include a growing emphasis on rsv prevention, rising vaccination rates in older adults, the expansion of adult immunization programs, vaccine delivery through hospital and community settings, and the provision of preventive care for high-risk populations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19948&type=smp

What Drivers Are Expected To Influence The Abrysvo Or Arexvy Market During The Forecast Period?

The abrysvo or arexvy market is projected to expand due to the rising occurrence of respiratory syncytial virus (RSV) infections. RSV, a common virus, primarily affects the respiratory system, typically causing mild cold-like symptoms but potentially resulting in severe illness for infants, older adults, and individuals with compromised immune systems. The escalating prevalence of RSV infections is attributed to its highly contagious nature, seasonal outbreaks, limited widespread immunity, and increased vulnerability among populations such as infants and the elderly. Abrysvo helps address RSV infections by offering targeted vaccines that shield high-risk populations, including older adults and infants, from severe respiratory syncytial virus-related illnesses. For instance, in Oct 2024, the Centers for Disease Control and Prevention, a US-based health protection agency, reported that during the 2024-25 season, the total hospitalization rate associated with RSV reached 3.2 per 100,000 individuals. Therefore, the growing prevalence of RSV infections is a key factor driving the growth of the abrysvo or arexvy market.

How Is The Abrysvo Or Arexvy Market Structured Across Different Segments?

The abrysvo or arexvy market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection

2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)

3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults

Which Trends Are Shaping The Future Of The Abrysvo Or Arexvy Market?

Leading companies within the abrysvo or arexvy market are focused on developing advanced products, such as bivalent prefusion F (RSVpreF) vaccines, aiming to broaden protection, enhance safety, and serve high-risk populations. Bivalent RSVpreF vaccines are formulations designed to provide immunity against both major RSV subgroups (RSV-A and RSV-B) by targeting the prefusion state of the fusion (F) protein, which is a critical site for neutralizing antibodies. For instance, in October 2024, Pfizer Inc., a US-based pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for ABRYSVO (RSV Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine. This approval is for preventing lower respiratory tract disease in adults aged 18 to 59 at increased risk, thus expanding its indication to cover the broadest adult population. It also remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 months.

Which Major Players Dominate The Abrysvo Or Arexvy Market?

Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK)

Read the full abrysvo or arexvy market report here:

https://www.thebusinessresearchcompany.com/report/abrysvo-or-arexvy-global-market-report

Which Region Is Forecast To Lead The Abrysvo Or Arexvy Market In Terms Of Market Size?

North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Abrysvo Or Arexvy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19948&type=smp

Browse Through More Reports Similar to the Global Abrysvo Or Arexvy Market 2026, By The Business Research Company

Business Intelligence Bi Vendors Market Report 2026

https://www.thebusinessresearchcompany.com/report/business-intelligence-bi-vendors-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795